Downloads Library

NOTE: BG Medicine has licensed and/or received written permission from the author(s) to share the digital materials below.
They are meant for your personal use and not meant to be re-distributed or re-purposed.


.

CLINICAL PRESENTATIONS
Galectin-3 and Outcomes in Patients with End-Stage Renal Disease. Data from the German Diabetes and Dialysis Study.
de Boer R, Wanner C, Blouin K, Drechsler C		 pdf_icon_web PDF, 209KB
Oral Abstract: HFSA, 2009, “Clinical Validation of a Novel Assay for Galectin-3 for Risk Assessment in Acutely Destabilized Heart Failure”
deFilippi C, Christenson R, Shah R, Bhardwaj A, Januzzi JL		 pdf_icon_web
PDF, 715KB
“Galectin-3 and Long-Term Mortality in Patients with Acutely Decompensated Heart Failure”
Shah RV, Bhardwaj A, van Kimmenade RRJ, Januzzi JL		 pdf_icon_web
PDF, 3.1MB
.
.
.

WEBINARS, VIDEO, and INTERACTIVE
WEBINAR: “Galectin-3 in Cardiac Remodeling and Heart Failure”
Rudolf A. de Boer, MD, PhD; University Medical Center Groningen		 winmedia_icon
Lo-Res: (35MB)
Hi-Res: (75MB)
.
.
.

ARTICLES

   
E-BOOK ARTICLE: “Galectin-3 in Heart Failure—Linking Fibrosis Remodeling, and Progression”
deFilippi CR and Felker GM. US Cardiology. 2010;7:67-70.
 ebook_icon2
PDF, 320KB
ARTICLE: “Prognostic Value of Galectin-3, a Novel Marker of Fibrosis, in Patients with Chronic Heart Failure: Data from the DEAL-HF Study””
Lok DJA, van der Meer P, et al. Clin Res Cardiol. 2010;99:323-8.
 pdf_icon_web
PDF, 225KB
ARTICLE: “Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients with Acute Heart Failure.”
van Kimmenade RR, Januzzi JL, et al. J Am Coll Cardiol. 2006;48:1217-24.
 pdf_icon_web
PDF, 508KB
.
.
.

POSTERS
POSTER: “Galectin-3 is a Strong Early Predictor of Mortality in Severe Congestive Heart Failure “
Rousseau M, Gruson D, Lepoutre T, Ahn SA, Cumps J, and Ketelslegers JM
Catholic University of Louvain, Brussels, Belgium 		pdf_icon_web PDF, 209KB
POSTER: “Plasma Galectin-3 is Associated with Near-Term Rehospitalization in Heart Failure”
de Boer RA, van Veldhuisen DJ, deFilippi C, Muntendam P, Adourian AS, Guo Y, and Januzzi J.
University Medical Center Groningen, Groningen, Netherlands
University of Maryland School of Medicine, Baltimore MD
BG Medicine Inc., Waltham, MA
Massachusetts General Hospital, Boston, MA		 pdf_icon_web PDF, 209KB
POSTER: “Changes in Galectin-3 Levels Over Time Predict Mortality and Morbidity in Heart Failure”
de Boer RA, van Veldhuisen DJ, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian AS, and Muntendam P.
University Medical Center Groningen, Groningen, Netherlands
Rikshospitalet University Hospital, Oslo, Norway
BG Medicine Inc., Waltham, MA		 pdf_icon_web PDF, 209KB
POSTER: “Pharmacological Inhibition of Galectin-3 Attenuates Adverse Cardiac Remodeling and Heart Failure”
Yu L, Ruifrok WP, Sillje HHW, Bos E, Van Goor H, Van Veldhuisen DJ, Van Gilst WH, De Boer RA
University Medical Center Groningen, Department of Cardiology, Groningen, Netherlands, University Medical Center, Department of Pathology		 pdf_icon_web PDF, 209KB
POSTER: “Genetic Disruption of Galectin-3 Prevents Adverse Cardiac Remodeling”
Yu L, Ruifrok WP, Sillje HHW, Bos E, Van Goor H, Van Veldhuisen DJ, Van Gilst WH, De Boer RA
University Medical Center Groningen, Department of Cardiology, Groningen, Netherlands, University Medical Center, Department of Pathology		 pdf_icon_web PDF, 209KB
POSTER: “Galectin-3, Cardiovascular Risk Factors, and Outcome in the General Population”
de Boer RA, Van Veldhuisen DJ, Gansevoort RT, Kobold ACM, Silljé HHW, Van Gilst WH, Hillege HL, Bakker SJL, Van Der Harst P. Departments of Cardiology, Internal Medicine, Laboratory Medicine, and Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands		 pdf_icon_web PDF, 209KB
POSTER: “Galectin-3 Predicts Mortality and Response to Statin Therapy in Chronic Heart Failure”
Gullestad L, Ueland T, Nymo S.H., Kjekshus J, Hulthe J, Muntendam P, Adourian A, McMurray JJV, Wikstrand J, Aukrust P
Oslo University Hospital, Rikshospitalet, Oslo, Norway		 pdf_icon_web PDF, 209KB
POSTER: “Analytical Performance of an Optimized ELISA for Galectin-3″
Smith A, Wu AH, Abel G, Christenson RH, Wang S;
University of California, San Francisco, San Francisco, CA;
Lahey Clinic, Burlington, MA; University of Maryland, Baltimore,
MD; BG Medicine Inc., Waltham, MA		 pdf_icon_web PDF, 209KB
POSTER: “Reference Interval for Plasma Galectin-3 in Healthy Subjects Age 55 Years and Older”
Muntendam P, Adourian A, Christenson RH;
BG Medicine Inc., Waltham, MA; University of Maryland Medical
Center, Baltimore, MD		 pdf_icon_web PDF, 131KB
POSTER: “Galectin-3 and PIIINP are Associated with Cardiovascular Outcomes in Patients with Heart Failure, Left Ventricular Dysfunction, and Dyssynchrony. Insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial”
Rossignol P, Iraqi W; Lopez-Andrès N, Fay R, Nuée J, Ghio S, Cleland J, Lacolley P, Zannad F;
CHU de Nancy, Department of Cardiology, Heart Failure and Hypertension Unit, Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu, Vandoeuvre-Lès Nancy, France; Inserm, Centre d’Investigation Clinique de Nancy CIC-P 9501, Vandoeuvre-les-Nancy, France; Nancy-Université, Faculté de Médecine, Vandoeuvre-lès-Nancy, France; Inserm U961, Nancy Université, Nancy, France; Department of Cardiology, University of Hull, Kingston upon Hull, UK		 pdf_icon_web PDF, 1.8MB